Core Viewpoint - Haisun Pharmaceutical has successfully renewed the contract for its product, Landeolol Hydrochloride Injection (50mg), and has newly included the 150mg specification in the National Medical Insurance Directory, which is expected to positively impact the company's long-term operations [1]. Group 1: Stock Performance - As of December 8, 2025, Haisun Pharmaceutical's stock closed at 52.31 yuan, up 2.09% from the previous trading day, with a total market capitalization of 6.277 billion yuan [1]. - The stock opened at 51.36 yuan, reached a high of 52.65 yuan, and a low of 51.31 yuan, with a trading volume of 2.26 billion yuan and a turnover rate of 5.28% [1]. Group 2: Product and Revenue Impact - The product Landeolol Hydrochloride Injection (50mg) has a reimbursement price of 168 yuan per unit, while the 150mg specification is set at 389.55 yuan per unit, with the same payment scope [1]. - The agreement for these products is effective from January 1, 2026, to December 31, 2027 [1]. - In 2024, the sales revenue from the 50mg specification is projected to be 337.77 million yuan, accounting for 67.27% of the company's total revenue [1]. - The renewal of the 50mg specification is not expected to affect performance, while the inclusion of the 150mg specification is anticipated to have a positive long-term impact on operations [1].

Group 1 - Cambridge Technology plans to invest 400 million yuan to establish a fund focused on optical devices and chips, aiming to invest in early-stage and growth-stage companies in the hard technology sector [1] - Tunnel Corporation's consortium won a bid for a highway project in Henan with a total investment of 6.49 billion yuan, using a BOT model for a 33.25-year cooperation period [2] - Hongrun Construction won a bid for a project worth 230 million yuan, which represents 3.88% of the company's projected revenue for 2024 [3] Group 2 - Tongrentang's product, Canling Baizhu Powder, received product registration approval from Health Canada, aimed at treating symptoms related to spleen and stomach weakness [4] - Hunan Baiyin announced a scheduled annual maintenance from December 9, 2025, to January 5, 2026, for equipment and facilities [5] - Changchun Gaoxin's subsidiary had two drugs included in the national medical insurance catalog for 2025 [6] Group 3 - Dongfang Securities' chairman resigned due to work relocation [7] - Xuantai Pharmaceutical's product, Sitagliptin Metformin Sustained-Release Tablets, was renewed for inclusion in the national medical insurance catalog [8] - ST Weihai was pre-selected for a smart agriculture EPC project with a bid of 652 million yuan, accounting for 26.27% of the company's projected revenue for 2024 [9] Group 4 - Guoxin Technology successfully tested an anti-quantum password financial POS chip, supporting both traditional and quantum-resistant algorithms [10] - Huaren Health's subsidiary received acceptance for a drug registration application for Lactulose Oral Solution, a common laxative [11] - Ankai Bus reported a 57.71% year-on-year increase in sales for the first 11 months of the year [12] Group 5 - Zhongyan Dadi's subsidiary won a bid for a project worth 73.86 million yuan [13] - Zhejiang Rongtai plans to invest 77 million USD in a factory in Thailand, focusing on mica paper and robot components production [14] - Optoelectronics plans to use up to 450 million yuan of idle funds for cash management [15] Group 6 - Tianyu Biological reported a 45.15% year-on-year decline in sales revenue from pig sales in November [16] - Daqin Railway's cargo transport volume increased by 1.75% year-on-year in November [17] - Yabo Co. won a bid for a heavy truck charging station project worth 3.616 million yuan [18] Group 7 - Hongri Pharmaceutical's product continues to be included in the national medical insurance catalog [19] - Jinggong Steel Structure signed a contract for steel structure installation worth approximately 470 million yuan for an overseas project [20] - Xizang Pharmaceutical's product, Xinhuasuan, continues to be included in the national medical insurance catalog [21] Group 8 - Guangdong Electric Power A announced the successful commissioning of a 1000MW unit at the Maoming Boge Power Plant [22] - Fuan Pharmaceutical's product, Palivizumab Injection, was newly included in the national medical insurance catalog [23] - Lizhu Group reported that 194 products were included in the 2025 national medical insurance catalog [24] Group 9 - Haisan Pharmaceutical's injection of Lantanol was included in the national medical insurance catalog [25] - Zhongtong Bus reported a 39.53% year-on-year increase in sales volume in November [26] - Shaanxi Coal Industry reported a 6.03% year-on-year increase in coal production in November [27] Group 10 - Haooubo's subsidiary received a medical device registration certificate for an IgG4 testing kit [28] - Yaopi Glass plans to invest 690 million yuan in new automotive glass production lines [30] - Huadian International completed the issuance of 2 billion yuan in medium-term notes [31] Group 11 - Zhongzai Zihuan's subsidiary won a bid for a green recycling project worth 205 million yuan [32] - Dabeinong reported a 25.26% year-on-year decline in sales revenue from pig sales in November [33] - Xiangjia Co. reported a 3.77% year-on-year increase in live poultry sales revenue in November [34] Group 12 - Huanxu Electronics reported a consolidated revenue of 5.198 billion yuan in November, a decrease of 3.34% year-on-year [35] - Aonong Biological reported a 72.21% year-on-year increase in pig sales volume in November [36] - Samsung Medical's subsidiary was pre-selected for a procurement project worth approximately 108 million yuan [37]

Core Viewpoint - The company, Hai Chen Pharmaceutical, successfully renewed the contract for its injectable Labetalol Hydrochloride (50mg) and has also included the 150mg version in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog for 2025 [1] Group 1 - The injectable Labetalol Hydrochloride (50mg) has successfully renewed its contract [1] - The injectable Labetalol Hydrochloride (150mg) has been included for the first time in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog for 2025 [1]

Core Insights - The National Healthcare Security Administration and the Ministry of Human Resources and Social Security have announced the inclusion of Nanjing Haichen Pharmaceutical's injectable Landeolol hydrochloride (50mg) in the National Medical Insurance Directory for 2025, and the first-time inclusion of injectable Landeolol hydrochloride (150mg) [1] Group 1 - Landeolol hydrochloride is a new generation of rapid-acting, ultra-short-acting, highly selective β1 receptor blocker, with a selectivity ratio of approximately 255 times for β1 over β2 receptors, and 8 times more selective than another ultra-short-acting β blocker, Esmolol [2] - The drug has a rapid onset of action (1 to 6 minutes post-administration), a short half-life of about 4 minutes, and minimal negative impact on cardiac hemodynamics and respiratory function [2] - Landeolol is recommended for controlling ventricular rate in acute heart failure patients according to the 2023 National Heart Failure Guidelines, and is also a recommended drug for acute atrial fibrillation in the 2024 Chinese Emergency Management Guidelines [2] Group 2 - The product is projected to achieve sales revenue of 337.77 million yuan in 2024, accounting for 67.27% of the company's total revenue, making it the company's main product [2]

Core Viewpoint - Haicheng Pharmaceutical has successfully renewed the inclusion of its injectable Labetalol Hydrochloride (50mg) and has achieved the first-time inclusion of injectable Labetalol Hydrochloride (150mg) in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog for 2025 [1] Group 1 - The National Healthcare Security Administration and the Ministry of Human Resources and Social Security have released a notification regarding the updated drug catalog for 2025 [1] - The successful renewal of the 50mg formulation indicates continued support for Haicheng Pharmaceutical's product line [1] - The first-time inclusion of the 150mg formulation expands the company's market access and potential revenue streams [1]

Group 1: Market Activity - 13 stocks had a closing order amount exceeding 100 million yuan, with the top four being Yiming Pharmaceutical (4.88 billion yuan), Zhongsheng Pharmaceutical (3.28 billion yuan), Jinying Co. (2.98 billion yuan), and Jianghuai Automobile (2.18 billion yuan) [3] - Yiming Pharmaceutical ranked first in closing order volume with 273,900 hands, followed by Zhongsheng Pharmaceutical and Yuheng Pharmaceutical, both exceeding 200,000 hands [2] Group 2: Company Announcements - Yiming Pharmaceutical announced that its actual controller, Gao Fan, signed a share transfer agreement to transfer 23% of the company's shares to Beijing Fuhai at a price of 15.1 yuan per share, totaling 662 million yuan [3] - The company reported revenues of 857 million yuan, 667 million yuan, and 652 million yuan for 2022, 2023, and 2024 respectively, with net profits of 44 million yuan, 15 million yuan, and 46 million yuan [3] Group 3: Sector Performance - The innovative drug sector saw several stocks hit the daily limit, including Changshan Pharmaceutical, Haichen Pharmaceutical, Shutaishen, and Ruizhizhi Pharmaceutical [4] - Haichen Pharmaceutical's main products include self-developed drugs that are selected in national drug procurement [4] Group 4: Investment Trends - The stocks with the highest net purchases on the Dragon and Tiger list included Changshan Pharmaceutical, Haichen Pharmaceutical, and Hahan Huatu, with net purchases exceeding 100 million yuan [8] - Institutions showed significant net buying in stocks like Kuaibao and Rejing Biological, while net selling was observed in Yuyin Co., Hengbao Co., and Xiongdi Technology [8]